BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 8570730)

  • 21. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate.
    Peng Q; Soler AM; Warloe T; Nesland JM; Giercksky KE
    J Photochem Photobiol B; 2001 Sep; 62(3):140-5. PubMed ID: 11566277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitization.
    Casas A; Fukuda H; Di Venosa G; Batlle AM
    Br J Dermatol; 2000 Sep; 143(3):564-72. PubMed ID: 10971330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo fluorescence kinetics and photodynamic therapy efficacy of delta-aminolevulinic acid-induced porphyrins in basal cell carcinomas and actinic keratoses; implications for optimization of photodynamic therapy.
    Stefanidou M; Tosca A; Themelis G; Vazgiouraki E; Balas C
    Eur J Dermatol; 2000; 10(5):351-6. PubMed ID: 10882942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism.
    Fritsch C; Verwohlt B; Bolsen K; Ruzicka T; Goerz G
    Arch Dermatol Res; 1996 Aug; 288(9):517-21. PubMed ID: 8874745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.
    Martin A; Tope WD; Grevelink JM; Starr JC; Fewkes JL; Flotte TJ; Deutsch TF; Anderson RR
    Arch Dermatol Res; 1995; 287(7):665-74. PubMed ID: 8534131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid.
    Fritsch C; Lehmann P; Stahl W; Schulte KW; Blohm E; Lang K; Sies H; Ruzicka T
    Br J Cancer; 1999 Mar; 79(9-10):1603-8. PubMed ID: 10188913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photodynamic therapy in dermatology.
    Fritsch C; Goerz G; Ruzicka T
    Arch Dermatol; 1998 Feb; 134(2):207-14. PubMed ID: 9487213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminolevulinic acid photodynamic therapy for skin cancers.
    Blume JE; Oseroff AR
    Dermatol Clin; 2007 Jan; 25(1):5-14. PubMed ID: 17126737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic diagnosis and therapy in dermatology.
    Fritsch C; Lang K; Neuse W; Ruzicka T; Lehmann P
    Skin Pharmacol Appl Skin Physiol; 1998; 11(6):358-73. PubMed ID: 10343206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome.
    Itkin A; Gilchrest BA
    Dermatol Surg; 2004 Jul; 30(7):1054-61. PubMed ID: 15209801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma.
    Peng Q; Warloe T; Moan J; Heyerdahl H; Steen HB; Nesland JM; Giercksky KE
    Photochem Photobiol; 1995 Nov; 62(5):906-13. PubMed ID: 8570730
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.